Myriad Genetics | MYGN - Selling And Administration Expenses


Myriad Genetics reported $122.3M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Agilent USD 475M 10M Jun/2026
Becton, Dickinson and Co. USD 1.26B 1000K Sep/2026
Bio-Rad Laboratories USD 212M 400K Jun/2026
Bruker USD 226.5M 12.4M Sep/2026
Danaher USD 2.16B 87M Sep/2026
Illumina USD 281M 8M Sep/2026
J&J USD 6.25B 168M Sep/2026
Mettler Toledo International USD 267.16M 3.82M Sep/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
OraSure Technologies USD 13.21M 3.29M Dec/2025
Pacific Biosciences Of California USD 37.24M 25.68M Dec/2025
Quest Diagnostics USD 523M 6M Sep/2026
Quidel USD 182.7M 7M Sep/2026
Repligen USD 83.59M 6.97M Sep/2026
Revvity USD 275.33M 3.25M Sep/2026
Standard Biotools USD 16.39M 2.22M Jun/2026
Thermo Fisher Scientific USD 1.86B 46M Sep/2026
Veracyte USD 57.95M 2.25M Sep/2026
Waters USD 398M 7M Sep/2026